Praxis Precision Medicines
PRAX
113 hedge funds and large institutions have $762M invested in Praxis Precision Medicines in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 43 increasing their positions, 25 reducing their positions, and 35 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 25
2% more funds holding
Funds holding: 111 → 113 (+2)
9% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 35
7% less call options, than puts
Call options by funds: $35.4M | Put options by funds: $38.1M
12.55% less ownership
Funds ownership: 120.24% → 107.68% (-13%)
22% less capital invested
Capital invested by funds: $971M → $762M (-$209M)
44% less funds holding in top 10
Funds holding in top 10: 9 → 5 (-4)
Top Buyers
| 1 |
BlackRock
New York
|
+$50.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$36.6M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$23.4M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$19.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19M |
Top Sellers
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$29.5M |
| 2 |
O
OrbiMed
New York
|
-$28.1M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$13.7M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$12.2M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.15M |
PRAX Hedge Fund Activity: Q2 2024 in Review
113 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q2 2024, worth a combined $762M — down 22% from $971M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new PRAX positions and 35 closed out — a net gain of 3 holders — while 43 added to existing stakes and 25 trimmed.
The largest buyer was BlackRock, adding an estimated $50.7M. The largest seller was Cormorant Asset Management, cutting an estimated $29.5M.
- 113 institutional investors held Praxis Precision Medicines (PRAX) as of Q2 2024, up from 111 in Q1 2024.
- Funds reported $762M of Praxis Precision Medicines stock for Q2 2024, down 22% quarter-over-quarter.
- 38 funds opened new Praxis Precision Medicines positions in Q2 2024 and 35 closed out, a net change of +3 holders.
- The largest Praxis Precision Medicines buyer in Q2 2024 was BlackRock, an estimated $50.7M added.
- The largest Praxis Precision Medicines seller in Q2 2024 was Cormorant Asset Management, an estimated $29.5M sold.
Based on aggregated 13F filings for Q2 2024.